** Orthocell OCC.AX jumps 7% to A$1.53; set for biggest intraday percentage gain since March 17
** Biotech firm receives U.S. FDA clearance to begin commercially distributing its flagship Remplir nerve repair product in the U.S.
** Stock sees busiest session since late February - 3.2 million shares traded, 2.1x the 30-day avg
** OCC gains 13.3% YTD
(Reporting by Jasmeen Ara Shaikh in Bengaluru)
((JasmeenAraIslam.Shaikh@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。